Qiagen to Gain Array-Based Breast Cancer Test through Ipsogen Buy
June 21, 2011
Qiagen to Gain Array-Based Breast Cancer Test through Ipsogen Buy
Qiagen's planned acquisition of Ipsogen will provide the firm with a suite of CE-IVD marked PCR tests as well as an Affymetrix-manufactured microarray test that can be used to guide treatment for breast cancer patients.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Fluidigm to Launch SNP Panel Designed to Help Biorepositories QC and ID Their Sample Collections
April 23, 2013 / BioArray News - Q&A: RUCDR's Andy Brooks on the Challenges Facing Biorepositories and the Rise of Biobank Arrays
April 23, 2013 / BioArray News - Scienion, Genomica Partner to Market Multiplexed Molecular Testing Platform
November 6, 2012 / BioArray News - CombiMatrix Bets on Array-Based Prenatal Testing, Affy Clinical Trials Deal to Drive Growth in H2
August 14, 2012 / BioArray News - Illumina Q2 Revenues Down 2 Percent
July 25, 2012 / GenomeWeb Daily News